Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Long-term cohort studies

Topic: Brain proteins, microglia and lab models

Plain-language summary

The final sample included 1196 cases (505 PD, 26 APD, 476 AD, 189 ALS) and 44,107 control subjects. In Cox regression models, NfL was associated with higher risk of incident ALS (HR 1.69; 95% CI, 1.58-1.80, p < 0.001), APD (HR 1.51; 95% CI, 1.22-1.87, p < 0.001), AD (HR 1.31; 95% CI, 1.22-1.41, p < 0.001), and PD (HR 1.14; 95% CI, 1.05-1.23, p < 0.001). GFAP was independently associated with incident AD only (HR 1.72; 95% CI, 1.63-1.82, p < 0.001). Plasma NfL and GFAP showed distinct pre-diagnostic profiles. NfL was associated with incident diagnosis of several neurodegenerative diseases, while GFAP was specific to AD, reinforcing its role in dementia. These results may help optimize the identification of target populations at risk of neurodegenerative diseases for future neuroprotective treatments.

What this study adds

Evidence grade: Low

The record lists 1,196 participants. In this UK Biobank analysis, higher plasma NfL was linked to later diagnosis of several neurodegenerative diseases including Alzheimer's disease, while higher GFAP was linked specifically to Alzheimer's disease. Reported effect size: HR 1.69; HR 1.51; HR 1.31.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Buonocore, J., Fratto, E., Arcuri, F., Vescio, B., Calomino, C., Talarico, M., et al. (2025). Plasma NfL and GFAP in the preclinical stages of neurodegenerative diseases: insights from the UK Biobank. Journal of Neurology. https://doi.org/10.1007/s00415-025-13498-y

Vancouver

Buonocore J, Fratto E, Arcuri F, Vescio B, Calomino C, Talarico M, et al. Plasma NfL and GFAP in the preclinical stages of neurodegenerative diseases: insights from the UK Biobank. Journal of Neurology. 2025. doi:10.1007/s00415-025-13498-y. PMID: 41206819.

BibTeX

@article{buonocore2025-41206819,
  author  = {Buonocore, Jolanda and Fratto, Enrico and Arcuri, Fulvia and Vescio, Basilio and Calomino, Camilla and Talarico, Mariagrazia and Cristiani, Costanza Maria and Quattrone, Aldo and others},
  title   = {{Plasma NfL and GFAP in the preclinical stages of neurodegenerative diseases: insights from the UK Biobank}},
  journal = {Journal of Neurology},
  year    = {2025},
  doi     = {10.1007/s00415-025-13498-y},
  pmid    = {41206819},
  url     = {https://doi.org/10.1007/s00415-025-13498-y}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In this UK Biobank analysis, higher plasma NfL was linked to later diagnosis of several neurodegenerative diseases including Alzheimer's disease, while higher GFAP was linked specifically to Alzheimer's disease. These blood markers may help identify people at risk of these diseases for future neuroprotective treatments, though the study does not test any treatment itself.

Study details

How this study scored 50/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 3 of 4; Effect reported 3 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 2 of 7; Citations per year 2 of 5; Impact for its field and year 4 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record 2 of 4; Institution's track record 1 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 50 of 100.50 of 100 points earned50 not earned

Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of Neurology)
Journal's citation record 2 / 4 Journal of Neurology: journal h-index 208 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 3 / 4 1,196 participants
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 2 / 7 Cited 14 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 4.7 citations a year over 3 year(s) since 2025
Impact for its field and year 4 / 6 Cited 8.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 14 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Andrea Quattrone: h-index 33 (OpenAlex, whole career)
Institution's track record 1 / 3 National Research Council: institution h-index 840 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41206819)
Free to read 2 / 2 Free to read
Total 50 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Long-term cohort studies from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Long-term cohort studies

See all studies in Long-term cohort studies →